{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:38:09Z","timestamp":1785530289705,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41440-025-02402-w","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T03:10:57Z","timestamp":1759979457000},"page":"3257-3267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of renin\u2013angiotensin system inhibitors in cancer patients: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"48","author":[{"given":"Satoshi","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hanajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Horigome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Tokoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Society of Hypertension (JSH) working group \u201cOnco-Hypertension\u201d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikiyo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kidoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nozato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2402_CR1","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397.","journal-title":"Eur Heart J"},{"key":"2402_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","volume":"7","author":"MS Ewer","year":"2010","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7:564\u201375.","journal-title":"Nat Rev Cardiol"},{"key":"2402_CR3","first-page":"309","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309\u201325.","journal-title":"CA Cancer J Clin"},{"key":"2402_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncol Pr. 2021;17:228\u201336.","journal-title":"JCO Oncol Pr"},{"key":"2402_CR5","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"2402_CR6","first-page":"943","volume":"50","author":"S Yano","year":"2023","unstructured":"Yano S. Onco-cardiology Guideline-Trends in Japan. Gan Kagaku Ryoho. 2023;50:943\u20139.","journal-title":"Gan Kagaku Ryoho"},{"key":"2402_CR7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2402_CR8","doi-asserted-by":"crossref","unstructured":"Center UMIN. UMIN Clinical Trials Registry (UMIN-CTR). https:\/\/www.umin.ac.jp\/ctr\/ctr_regist.htm. Accessed March 10 2025.","DOI":"10.15294\/jpk.v10i1.7367"},{"key":"2402_CR9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2402_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85:894\u20136.","journal-title":"Am J Hematol"},{"key":"2402_CR11","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.21873\/anticanres.13769","volume":"39","author":"P Georgakopoulos","year":"2019","unstructured":"Georgakopoulos P, Kyriakidis M, Perpinia A, Karavidas A, Zimeras S, Mamalis N, et al. The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients. Anticancer Res. 2019;39:5703\u20137.","journal-title":"Anticancer Res"},{"key":"2402_CR12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671\u201380.","journal-title":"Eur Heart J"},{"key":"2402_CR13","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2\u2009\u00d7\u20092 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021;143:2431\u201340.","journal-title":"Circulation"},{"key":"2402_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.33963\/KP.15163","volume":"78","author":"A S\u0142owik","year":"2020","unstructured":"S\u0142owik A, Jagielski P, Potocki P, Streb J, Ochenduszko S, Wysocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020;78:131\u20137.","journal-title":"Kardiol Pol"},{"key":"2402_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol. 2017;17:130\u20139.","journal-title":"Cardiovasc Toxicol"},{"key":"2402_CR16","doi-asserted-by":"publisher","first-page":"487.e1","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G, Deidda M, Dess\u00ec M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487.e1\u20137.","journal-title":"Am Heart J"},{"key":"2402_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3892\/etm.2011.305","volume":"2","author":"M Dess\u00ec","year":"2011","unstructured":"Dess\u00ec M, Piras A, Madeddu C, Cadeddu C, Deidda M, Massa E, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med. 2011;2:1003\u20139.","journal-title":"Exp Ther Med"},{"key":"2402_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35:870\u20137.","journal-title":"J Clin Oncol"},{"key":"2402_CR19","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019;73:2859\u201368.","journal-title":"J Am Coll Cardiol"},{"key":"2402_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, et al. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016;2:1030\u20137.","journal-title":"JAMA Oncol"},{"key":"2402_CR21","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474\u201381.","journal-title":"Circulation"},{"key":"2402_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.31557\/APJCP.2020.21.2.325","volume":"21","author":"M Dehghani","year":"2020","unstructured":"Dehghani M, Mirzaie M, Farhadi P, Rezvani A. The Effect of ACE Inhibitor on the Quality of Life amongst Patients with Cancer Cachexia. Asian Pac J Cancer Prev. 2020;21:325\u201330.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2402_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ijrobp.2018.10.035","volume":"103","author":"TT Sio","year":"2019","unstructured":"Sio TT, Atherton PJ, Pederson LD, Zhen WK, Mutter RW, Garces YI, et al. Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial. Int J Radiat Oncol Biol Phys. 2019;103:686\u201396.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2402_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/COC.0000000000000289","volume":"41","author":"W Small","year":"2018","unstructured":"Small W, James JL, Moore TD, Fintel DJ, Lutz ST, Movsas B, et al. Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol. 2018;41:396\u2013401.","journal-title":"Am J Clin Oncol"},{"key":"2402_CR25","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"2402_CR26","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.31557\/APJCP.2021.22.9.2847","volume":"22","author":"A Wihandono","year":"2021","unstructured":"Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. Asian Pac J Cancer Prev. 2021;22:2847\u201353.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2402_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","volume":"26","author":"K Fang","year":"2021","unstructured":"Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2021;26:101\u20139.","journal-title":"Heart Fail Rev"},{"key":"2402_CR28","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"key":"2402_CR29","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1002\/cam4.3956","volume":"10","author":"M Lee","year":"2021","unstructured":"Lee M, Chung WB, Lee JE, Park CS, Park WC, Song BJ, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021;10:3964\u201373.","journal-title":"Cancer Med"},{"key":"2402_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.archger.2010.04.022","volume":"53","author":"M Motta","year":"2011","unstructured":"Motta M, Russo C, Vacante M, Liardo RL, Reitano F, Cammalleri L, et al. Losartan vs. amlodipine treatment in elderly oncologic hypertensive patients: a randomized clinical trial. Arch Gerontol Geriatr. 2011;53:60\u20133.","journal-title":"Arch Gerontol Geriatr"},{"key":"2402_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/abr.abr_81_21","volume":"12","author":"SM Hashemi Jazi","year":"2023","unstructured":"Hashemi Jazi SM, Tayebi F, Teimouri-Jervekani Z, Mokarian F, Mehrzad V, Sadeghi A. Comparative Evaluation of Captopril, Spironolactone, and Carvedilol Effect on Endothelial Function in Breast Cancer Women Undergoing Chemotherapy. Adv Biomed Res. 2023;12:116.","journal-title":"Adv Biomed Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02402-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:50Z","timestamp":1764889310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02402-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02402-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Mikio Mukai has received speaking honoraria from Daiichi Sankyo and Ferring Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}